Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
about
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerAdverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunctionThe efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function.Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.Renal effects of targeted anticancer therapies.The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer.Nephrotoxicity of anticancer treatment.Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment.Anticancer Drug-Induced Acute Kidney Injury.Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.Progressive renal insufficiency related to ALK inhibitor, alectinib.Crizotinib-induced toxicity in an experimental rat model.Renal Injury during Long-Term Crizotinib Therapy
P2860
Q26784298-8F63B6FF-0431-4C19-8142-424BCC67D2F4Q33879009-492CC3FF-BF67-4F47-8F2F-D30CDE220346Q34268266-5E7FF7C2-301B-45C9-BBD8-A8EED6D32035Q34695551-0C265EB3-E205-44E5-B334-A8E63CC0CD2FQ37697125-0B87DBE0-8E32-481D-9877-CF3DBA328028Q38367168-18251CCE-97A5-4FB9-A6ED-C1A6CDF8D86DQ38716267-B002F975-F928-41AE-8A11-01FC5E3A5542Q38872183-0F9D3707-1F8F-4C0F-9CD7-336ED1931496Q39198933-695A0A4A-7C9D-4EA4-9EF9-3AFEDAD06410Q41488505-2B65B074-02DB-48DA-B9D9-B1005504749EQ47261056-1506FA28-D11E-4958-9E46-31A94FEF5FF0Q47841017-39F4EF01-83A3-4903-ACE1-E36D8D0536FAQ49188770-E4956BC5-1169-4307-B4D6-433D359A10A0Q52715325-A5C8915A-3F4F-40D1-BE11-0AEEDBF09905Q53148505-48D81277-1C7E-4262-AA96-EC226B408FA6Q59133910-F178990F-8602-4470-AEF5-03FF7FE02C4E
P2860
Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@en
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@nl
type
label
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@en
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@nl
prefLabel
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@en
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@nl
P2093
P2860
P356
P1433
P1476
Drug-induced reduction in esti ...... the ALK inhibitor crizotinib.
@en
P2093
Andrew J Weickhardt
Anna E Barón
D Ross Camidge
Delee A Maxon
Evelyn M Brosnan
Michel Chonchol
P2860
P304
P356
10.1002/CNCR.28478
P407
P577
2013-11-20T00:00:00Z